Myositis Interstitial Lung Disease Nintedanib Trial

Overview

This research study will evaluate safety and how well the study drug, nintedanib improve symptoms in participants with myositis associated interstitial lung disease (MA-ILD). Interstitial lung disease is a disorder caused by the abnormal accumulation of cells structures between air sacs of the lungs resulting in thickening, stiffness and scarring of the tissues of the lung.

This study will enroll a total of 134 participants across 15 clinical sites located in the United States. A subset of participants will be enrolled remotely via telemedicine utilizing certified mobile home research nurses and various remote monitoring devices.

The research visits may include a physical exam, vital signs (such as blood pressure, heart rate, etc.), pulmonary function tests (PFT and/or home spirometry), Computerized Tomography (or CT) scans of the chest, blood draws, wearing a physical activity monitor and completing questionnaires. Some of these events may be done at home, at a local facility or remotely (via telemedicine).

Description

Participants enrolled in the study will receive either study drug or placebo for 12 weeks plus the participant's normal standard of care medication for the participant's disease. Placebo is an inactive substance that contains no medicine. Following the initial treatment phase, participants will receive the active study drug (nintedanib) for an additional 12-week period.

Nintedanib is a drug that is currently used and has been approved by the Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF), and has been shown to slow the rate of decline in pulmonary function among patients with IPF as well as interstitial lung disease (ILD) associated with systemic sclerosis or scleroderma. In addition, in March 2020, the FDA approved nintedanib oral capsules to treat patients with chronic fibrosing (scarring) interstitial lung diseases (ILD) with a progressive phenotype (trait).

Eligibility

Inclusion Criteria:

1. Subject has provided written informed consent
2. Approval from local treating physician (done at pre-screening only for remote patients as well as for local site patients not actively being managed at the local site).
3. Subject lives in the United States
4. Adult: Age ≥ 18 years
5. Subject can speak, read, and understand English or Spanish
6. Subject is willing and capable of performing all study procedures.
7. Validity/repeatability of home spirometry confirmed by PFT lab technician/MD through telemedicine as per American Thoracic Society guidelines.
8. Men and women of reproductive potential must agree to use 2 reliable methods of birth control during the trial period.
9. Confirmed diagnosis of myositis (2017 American College of Rheumatology/European League Against Rheumatism classification criteria or presence of one of the following myositis-specific or -associated autoantibodies).
   1. Anti-synthetase autoantibody (Anti-Jo-1, -PL-7, -PL-12, -EJ, -OJ, -KS, -Tyr, -Zo)
   2. Anti-MDA5, TIF1-gamma, Mi-2, NXP2/MJ, SAE, HMGCR, SRP
   3. Anti-PM/Scl, Ku, U1RNP, Ro5,2/60, or SSA (in absence of clinical diagnosis of systemic sclerosis or primary Sjogren syndrome).
10. Fibrosing Interstitial Lung Disease (ILD):
    1. HRCT chest within 12 months of screening visit with fibrosing ILD (reticular changes, traction bronchiectasis, and/or honeycombing)
    2. No other identifiable cause of fibrosis
    3. The following co-existing features are expected and accepted: ground glass opacity, upper lung or peri-bronchovascular predominance, mosaic attenuation, air trapping, consolidation, and centrilobular nodules.
11. Progressive ILD: Defined as meeting ≥1 of the following criteria within 24 months of

    the screening visit.

    1. ≥10% relative decline in FVC% predicted (%pred)
    2. ≥5 but <10% relative decline in FVC %pred with worsening dyspnea.
    3. ≥5 but <10% relative decline in FVC %pred with worsening chest HRCT fibrotic changes
    4. Worsening dyspnea with worsening chest HRCT fibrosis
12. The severity of ILD: FVC > 40% of predicted and ≤ 80% of predicted.
13. Standard of care (SOC) therapy: (See: SOC immunosuppression and washout under section 6.2 for details)
    1. Allowable SOC includes a maximum of 2: 1 glucocorticoid (GC) and 1 Non-GC immunosuppressive medication (IS) Or 2 Non-GC immunosuppressive medications.
    2. Allowable IS component of SOC regimen must have been started at least 12 weeks prior and be stable for at least 4 weeks before screening visit.
    3. Allowable GC component of SOC regimen must have been started at least 4 weeks prior and be stable for at least 2 weeks before screening visit.
    4. Allowable IS and GC:

       Glucocorticoid (maximum dose ≤20 mg/day; prednisone equivalent). Mycophenolate mofetil (max dose 3 gm/day) Mycophenolic acid (max dose 1440 mg/day) Azathioprine (max dose 2.5 mg/kg/day) Methotrexate (max dose 25 mg/week Tacrolimus (max dose 10 mg/day) Cyclosporine (max dose 200 mg/day) Leflunomide (max dose 20 mg/day) Sulfasalazine (max dose 3 gm/day) IVIG (Intravenous immunoglobulin) or SQIG (subcutaneous immunoglobulin) (max dose 2 gm/kg/month) is allowed and not considered as SOC IS therapy Rituximab (maximum dose 1000 mg x 2 (2 weeks apart) or 375mg/m2 weekly dose x 4, repeated every > 4 months) Hydroxychloroquine is allowed and not considered as SOC IS therapy.

    5. Inhaled medication(s) for lung disease is allowed if started > 4 weeks before screening.

Should remain stable throughout the study.

14. Negative pregnancy test

Exclusion Criteria:

1. Planned major surgical procedures within the trial period of 24 weeks.
2. Women who are pregnant, nursing, or who plan to become pregnant while in the trial.
3. Women of childbearing potential* not willing or able to use at least two highly effective methods of birth control.
   1. For females of reproductive potential: use of highly effective contraception for at least 1 month before study drug administration and agreement to use such a method during study participation and for an additional 28 days after the end of study drug administration.
   2. For males of reproductive potential**: use of condoms or other methods to ensure effective contraception with a partner

Highly effective contraception examples are:

• An approved hormonal contraceptive such as oral contraceptives, emergency contraception used as directed, patches, implants, injections, rings, hormonally-impregnated intrauterine device (IUD), or nonhormonal IUD.
  • A woman is considered of childbearing potential, i.e. fertile, following menarche, and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, tubal occlusion, and bilateral oophorectomy.
    • A man is considered permanently sterile if a vasectomy has been performed. 4. Severe lung disease is defined by the following within the last 6 months before the

      screening

      1. FVC ≤40 percent predicted
      2. DLCO <30% of percent predicted (corrected for Hb)
      3. O2 requirement of ≥10 L at rest based on home oxygen prescription.
      4. Patient listed for lung transplant or actively going through lung transplant evaluation.
      5. Moderate to severe active muscle disease from myositis as per any one of the criteria:
      6. Creatine kinase (CK) > 1000 U/mL.
      7. Moderate to severe dermatomyositis rashes as per investigator evaluation (if rash present)
      8. Moderate to severe arthritis as per investigator evaluation
      9. Moderate to severe muscle weakness as per Sit to Stand 30 seconds of < 7.
      10. History of or ongoing serious active, chronic, or recurrent infection within 4 weeks

          of screening

      11. Significant Pulmonary Hypertension (PH) is defined by any of the following:
      12. Previous clinical diagnosis of moderate to severe PH or significant right heart failure.
      13. History of echocardiographic evidence of significant right heart failure or moderate to severe PH (TR jet >= 2.9 m/s and signs of right ventricle (RV) dysfunction; or TR jet > 3.4; or an right ventricle systolic pressure (RVSP) > 40-55 with evidence of RV strain or dysfunction; or RVSP > 55 regardless.
      14. History of right heart catheterization showing a cardiac index ≤ 2.2 l/min/m² or severity of pulmonary hypertension (mPAP) >40 millimeters of mercury (mmHg) with a pulmonary capillary wedge pressure (PCWP) <15mmHg
      15. PH requiring oral, IV, or inhaled therapy (such as epoprostenol, treprostinil, iloprost, bosentan, ambrisentan, sildenafil, and tadalafil).
      16. Increased bleeding risk, defined by any of the following:
      17. Patients who require

  • Fibrinolysis, full-dose therapeutic anticoagulation (e.g. vitamin K

    antagonists, direct thrombin inhibitors, heparin, factor Xa inhibitors, low molecular weight heparin)

  • High dose antiplatelet therapy (>325mg acetylsalicylic acid or >75mg clopidogrel). 2. History of hemorrhagic central nervous system (CNS) event within 12 months of

    screening.

    3. Any of the following within 3 months of screening:
  • Hemoptysis or hematuria
  • Active gastrointestinal (GI) bleeding or active GI ulcers. 4. Coagulation parameters: International normalized ratio (INR) >2, prolongation of

    prothrombin time (PT) and activated partial thromboplastin time (aPTT) by >1.5 x ULN at screening.

    9. History of a thrombotic event (including stroke and transient ischemic attack) within

    12 months of screening.

    10. Severe Cardiovascular disease, any of the following:
    1. Severe hypertension, uncontrolled under treatment (≥160/100 mmHg), within 6 months of screening.
    2. Myocardial infarction or unstable cardiac angina within 6 months of screening.
    3. Patients with underlying chronic liver disease (Child-Pugh A, B, or C hepatic

       impairment).

    4. Known hypersensitivity to the trial medication or its components (i.e. soya lecithin)
    5. Other diseases that may interfere with testing procedures or in the judgment of the

       Investigator may interfere with trial participation (such as significant GI issues like irritable bowel syndrome, inflammatory bowel disease, recent abdominal surgery, diverticular disease), or significant other lung diseases (such as severe obstructive lung disease such as severe asthma or severe chronic obstructive pulmonary disease, etc.) or may put the patient at risk when participating in this trial.

    6. Life expectancy for a disease other than ILD < 2.5 years (Investigator assessment).
    7. In the opinion of the investigator, any condition precluding participation and

       completion of the study, including active alcohol and drug abuse or patients not able to understand or follow trial procedures.

    8. Other investigational therapy was received within 1 month or 6 half-lives (whichever

       was greater) before the screening visit.

    9. Previous treatment with nintedanib or pirfenidone (taken the drug for ≥ 1 month or

       history of intolerance/side effects)

    10. Current or recent use of one or more of the following medications (See: SOC

        immunosuppression and washout under section 6.2 for details)

    11. Cyclophosphamide within 3 months of baseline.
    12. Anti-tumor necrosis factor (infliximab, golimumab, or certolizumab) within 8 weeks or adalimumab within 4 weeks, and etanercept within 2 weeks of baseline.
    13. Janus kinase inhibitors (tofacitinib, upadacitinib, baricitinib, others) within 4 weeks of baseline.
    14. Anakinra within 1 week of baseline.
    15. Other biological agents such as tocilizumab, abatacept, etc. within 4 weeks of baseline.
    16. Safety laboratory abnormality as any one of below
    17. Aspartate transferase (AST), alanine aminotransferase (ALT) > 1.5 x ULN at screening, unless deemed due to active myositis, in which case CK is also abnormally elevated and the ratio of AST or ALT by CK levels (adjusted as x ULN) should be < 2.0 and gamma-glutamyl transferase < 2.0 x ULN.
    18. Bilirubin > 1.5 x ULN at screening
    19. Creatinine clearance <30 mL/min calculated by Cockcroft-Gault formula at screening.
    20. Hgb < 9.0
    21. Platelet count < 100,000/mm3
    22. White blood cells < 3000/mm3

        -